CEO Pershing Edward Buys 1.3 Million Preferred Shares, Boosting Stake to 2.6 Million in Provectus Biopharma
CEO Pershing Edward’s latest buy of Provectus’s convertible preferred shares signals confidence in the oncology pipeline and may stabilize volatility for long‑term investors.
- Provectus Biopharmaceuticals Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read